Clicky

BiondVax Pharmaceuticals Ltd.(BVXV)

Description: BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, develops universal influenza vaccine. Its lead product is the Multimeric-001 universal flu vaccine, which has completed two Phase II and two Phase I/II clinical trials to provide multi-season and multi-strain protection against human influenza virus strains, including seasonal and pandemic flu strains. The company was founded in 2003 and is based in Ness Ziona, Israel.


Keywords: Medicine Biopharmaceutical Drugs Vaccines Influenza Vaccination Influenza Vaccine Biondvax Human Influenza Universal Flu Vaccine Universal Influenza

Home Page: www.biondvax.com

BVXV Technical Analysis

Jerusalem BioPark Building
Jerusalem,
Israel
Phone: 972 8 930 2529


Officers

Name Title
Mr. Amir Reichman M.B.A., M.Sc. CEO & Director
Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA Chief Financial Officer
Mr. Elad Mark B.Sc., Eng., M.B.A. Chief Operating Officer
Dr. Tamar Ben-Yedidia Ph.D. Chief Scientist
Mr. Joshua E. Phillipson B.Sc., M.B.A. Director of Bus. Devel. & Investor Relations
Ms. Moran Ahdout Fruchter L.L.B. Chief of Staff
Ms. Dalit Weinstein Fischer Head of Technical R&D

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 7.4836
Price-to-Sales TTM: 0
IPO Date: 2015-05-12
Fiscal Year End: December
Full Time Employees: 15
Back to stocks